Product Data Sheet

NLG919



Cat. No.: A4373

CAS No.: 1402836-58-1

Formula: C18H22N2O

M.Wt: 282.38

Synonyms:

Target: Metabolism

Pathway: IDO

Storage: Store at -20°C

Solvent & Solubility

In Vitro

insoluble in H2O; insoluble in EtOH; ⩾47.7 mg/mL in DMSO

Preparing Stock Solutions

Mass / Solvent / Concentration	1mg	5mg	10mg
1 mM	3.5413 mL	17.7066 mL	35.4133 mL
5 mM	0.7083 mL	3.5413 mL	7.0827 mL
10 mM	0.3541 mL	1.7707 mL	3.5413 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Potent IDO pathway inhibitor
IC_{50} & Target	7 nM (Ki) (IDO pathway)

In Vitro

Cell Viability Assay

Cell Line:	Human and mouse IDO+ pDCs
Preparation method:	Limited solubility. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	37°C

	Applications:	NLG919 potently blockes IDO-induced T cell suppression and restores robust T cell responses with an EC50=90 nM. NLG919 also abrogates IDO-induced suppression of antigen-specific T cells (OT-I or pmel-1) in vitro, (ED50=130 nM) using mouse IDO+ pDCs from tumor-draining lymph nodes.
In Vivo	**Animal experiment**	
	Animal models:	Mice bearing large established B16F10 tumor
	Dosage form:	NLG919 was dosed either dissolved in the water at 3 mg/mL, plus a daily dose of 6 mg injected via IP, or administered subcutaneously at 1 mg/dose twice a day via injection plus 360 μg/day via an SC osmotic pump.
	Applications:	NLG919 markedly enhances the antitumor responses of naive, resting pmel-1 cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA. NLG919 plus pmel-1/vaccine produces a dramatic collapse of tumor size within 4 days of vaccination (~95% reduction in tumor volume compared to control animals receiving pmel-1/vaccine alone without NLG919).
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

Product Citations

1. Sun C, He D, et al. "Bifunctional fusion proteins derived from Tumstatin and 4-1BBL for targeted cancer therapy." Mol Pharm. 2018 Dec 19.PMID:30565463

See more customer validations on www.apexbt.com.

References

1. Mario R. Mautino, Firoz A et al. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 491.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology
www.apexbt.com
7505 Fannin street, Suite 410, Houston, TX 77054.
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com